In cancer, the therapeutic benefit is to halt EMT driven invasion, metastasis, and associated therapy resistance, with a focus on tumour type, microenvironmental modulators (e.g., NETs, TEVs), and sensor specificity (NLRP3 versus AIM2 oligomerisation) while also preserving normal host immune defences. The gene discussed is AIM2; the disease is neoplasm.